Literature DB >> 33732292

Immunoregulatory therapy strategies that target cytokine storms in patients with COVID-19 (Review).

Xianyao Wang1,2,3, Zhixu He2,4, Xing Zhao1,2,3.   

Abstract

A cytokine storm is an uncontrolled, excessive immune response that contributes to the pathogenesis of coronavirus disease 2019 (COVID-19). Viral infections lead to the loss of negative feedback in immune regulation and an abnormal elevation of the levels of multiple cytokines. In COVID-19, this causes diffuse damage to alveolar functions and may culminate in multiple organ dysfunction. Immunoregulatory therapies target the cytokine storms induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, and include monoclonal antibodies, recombinant granulocyte-macrophage colony stimulating factor, interferon, mesenchymal stem cell-based therapy, thymosin, immunoglobulins and blood purification therapies. These approaches may be effective in the alleviation of COVID-19 symptoms. In this review, cytokine storms caused by SARS-CoV-2 infections are evaluated and discussed, and advances in immunoregulatory therapy strategies for patients with COVID-19 are reviewed.
Copyright © 2020, Spandidos Publications.

Entities:  

Keywords:  COVID-19; SARS-CoV-2; cytokine storm; immunoregulatory therapy strategies

Year:  2021        PMID: 33732292      PMCID: PMC7903484          DOI: 10.3892/etm.2021.9750

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  79 in total

1.  Beyond dialysis: current and emerging blood purification techniques.

Authors:  Bernd Stegmayr; Wolfgang Ramlow; Rasheed A Balogun
Journal:  Semin Dial       Date:  2012 Mar-Apr       Impact factor: 3.455

2.  Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China.

Authors:  Ling Mao; Huijuan Jin; Mengdie Wang; Yu Hu; Shengcai Chen; Quanwei He; Jiang Chang; Candong Hong; Yifan Zhou; David Wang; Xiaoping Miao; Yanan Li; Bo Hu
Journal:  JAMA Neurol       Date:  2020-06-01       Impact factor: 18.302

3.  Potential role of thymosin in the treatment of autoimmune diseases.

Authors:  A L Goldstein; M M Zatz; T L Low; R Jacobs
Journal:  Ann N Y Acad Sci       Date:  1981       Impact factor: 5.691

Review 4.  Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock.

Authors:  Marissa M Alejandria; Mary Ann D Lansang; Leonila F Dans; Jacinto Blas Mantaring
Journal:  Cochrane Database Syst Rev       Date:  2013-09-16

5.  Thymosin alpha-1-transformed Bifidobacterium promotes T cell proliferation and maturation in mice by oral administration.

Authors:  Congwen Shao; Guojun Tian; Yuanjian Huang; Wenying Liang; Hang Zheng; Jiannan Wei; Cheng Wei; Cuilan Yang; Hong Wang; Weisen Zeng
Journal:  Int Immunopharmacol       Date:  2013-01-24       Impact factor: 4.932

Review 6.  COVID-19 and immunomodulation in IBD.

Authors:  Markus F Neurath
Journal:  Gut       Date:  2020-04-17       Impact factor: 23.059

7.  [Tocilizumab plus glucocorticoids in severe and critically COVID-19 patients. A single center experience].

Authors:  Gustavo Jiménez-Brítez; Pablo Ruiz; Xavier Soler
Journal:  Med Clin (Barc)       Date:  2020-07-09       Impact factor: 1.725

8.  Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study.

Authors:  Nanshan Chen; Min Zhou; Xuan Dong; Jieming Qu; Fengyun Gong; Yang Han; Yang Qiu; Jingli Wang; Ying Liu; Yuan Wei; Jia'an Xia; Ting Yu; Xinxin Zhang; Li Zhang
Journal:  Lancet       Date:  2020-01-30       Impact factor: 79.321

9.  Mesenchymal stem cells generate a CD4+CD25+Foxp3+ regulatory T cell population during the differentiation process of Th1 and Th17 cells.

Authors:  Patricia Luz-Crawford; Monica Kurte; Javiera Bravo-Alegría; Rafael Contreras; Estefania Nova-Lamperti; Gautier Tejedor; Danièle Noël; Christian Jorgensen; Fernando Figueroa; Farida Djouad; Flavio Carrión
Journal:  Stem Cell Res Ther       Date:  2013-06-04       Impact factor: 6.832

Review 10.  Coronavirus disease 2019 (COVID-19): cytokine storms, hyper-inflammatory phenotypes, and acute respiratory distress syndrome.

Authors:  Shi-Hui Lin; Yi-Si Zhao; Dai-Xing Zhou; Fa-Chun Zhou; Fang Xu
Journal:  Genes Dis       Date:  2020-06-29
View more
  6 in total

Review 1.  Current Strategies in Treating Cytokine Release Syndrome Triggered by Coronavirus SARS-CoV-2.

Authors:  Long G Wang; Luxi Wang
Journal:  Immunotargets Ther       Date:  2022-05-18

2.  Global Trends in Research of Macrophages Associated With Acute Lung Injury Over Past 10 Years: A Bibliometric Analysis.

Authors:  Sheng Wang; Huanping Zhou; Li Zheng; Wanli Zhu; Lina Zhu; Di Feng; Juan Wei; Guannan Chen; Xiaohong Jin; Hao Yang; Xuan Shi; Xin Lv
Journal:  Front Immunol       Date:  2021-05-20       Impact factor: 7.561

Review 3.  Interleukin-6 in SARS-CoV-2 induced disease: Interactions and therapeutic applications.

Authors:  Jamal Majidpoor; Keywan Mortezaee
Journal:  Biomed Pharmacother       Date:  2021-11-12       Impact factor: 7.419

4.  Adjunctive viral cell culture supports treatment decision-making in patients with secondary humoral immunodeficiency and persistent SARS-CoV-2 infection.

Authors:  Scott J C Pallett; Rachel Wake; Jonathan Youngs; Cassie Pope; Ngee Keong Tan; Joshua Taylor; Lois Hawkins; Adam A Witney; Kenneth G Laing; Irene M Monahan; Melek Akay; Alison Cox; Elisabetta Groppelli; Peter Kelleher; Paul Miller; Tihana Bicanic
Journal:  Br J Haematol       Date:  2021-11-11       Impact factor: 8.615

5.  Delayed COVID-19-induced cytokine storm after root canal therapy with favorable response to plasmapheresis, tocilizumab, and methylprednisolone pulses therapy: A case report.

Authors:  Fatemeh Aghaeimeybodi; Mohammad Moein Derakhshan Barjoei; Mohammad Mohammadi; Hamidreza Ghasemirad; Samrad Mehrabi
Journal:  Clin Case Rep       Date:  2022-07-22

Review 6.  SARS-CoV-2 Infection and Lung Regeneration.

Authors:  Fuxiaonan Zhao; Qingwen Ma; Qing Yue; Huaiyong Chen
Journal:  Clin Microbiol Rev       Date:  2022-02-02       Impact factor: 50.129

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.